Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tongjitang Pins Loss On Delayed Implementation Of China's Essential Drug List; Proposed Buyout Still Under Review

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Tongjitang, the first traditional Chinese medicine company listed on the New York Stock Exchange, reported a $694,000 net loss during the second quarter for the year, attributing it to increased sales and marketing expenses for sales infrastructure and its essential drug sales network
Advertisement

Related Content

Local Chinese Companies With Mix Of TCM And Western Medicines Poised For Strong Growth
Local Chinese Companies With Mix Of TCM And Western Medicines Poised For Strong Growth
3SBIO Sees Slowdown In China Regulatory Approvals Following SFDA Restructure; Concerns Linger On Drug Pricing Examination
China's Generic Companies Leaning Toward Innovation To Target Global Market: FT China Healthcare And Life Science Summit
China's Tongjitang Mulls Merger Proposal
China's Minister Of Health Calls For More Regional Support For Healthcare Reform
China Releases First Part Of Essential Drug List For Community Health Clinics And Rural Hospitals
China Releases First Part Of Essential Drug List For Community Health Clinics And Rural Hospitals
Shanghai Fosun Omni Pharma Execs On The Market For Inhalation Products In China: An Interview With PharmAsia News (Part 2 of 2)
Advertisement
UsernamePublicRestriction

Register

SC075733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel